Drugs / QR-1123
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04123626 | Oct 2019 → Jun 2022 overdue | retinitis, retinitis pigmentosa, vision disorder | ProQR Therapeutics | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2021-11-18 | ProQR Therapeutics | Results ProQR Announces Highlights from Analyst Event proqr.com ↗
A single dose of QR-1123 (gapmer) showed early evidence of target engagement and was well tolerated with no serious adverse events. |
| 2019-11-21 | ProQR Therapeutics | Regulatory ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa proqr.com ↗
ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it received Orphan Drug designation (ODD) from the Food and Drug Administration (FDA) for QR-1123. |
| 2019-09-09 | ProQR Therapeutics | Regulatory ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa proqr.com ↗ |
| 2019-08-12 | ProQR Therapeutics | Regulatory ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP) proqr.com ↗ |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-11-18 | ProQR Therapeutics | ProQR Announces Highlights from Analyst Event proqr.com ↗ |
| 2019-12-11 | ProQR Therapeutics | ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa proqr.com ↗ |
| 2019-11-21 | ProQR Therapeutics | ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa proqr.com ↗ |
| 2019-09-09 | ProQR Therapeutics | ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa proqr.com ↗ |
| 2019-08-12 | ProQR Therapeutics | ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP) proqr.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QR-1123 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04123626 ↗ |
| Action | Inhibit | “in order to reduce the expression of the P23H protein selectively” NCT04123626 ↗ |
| Modality | Antisense oligonucleotide | “QR-1123 is an antisense oligonucleotide” NCT04123626 ↗ |
| Route | Intravitreal | “unilateral IVT injection” NCT04123626 ↗ |